Trending Topic

Acute myeloid leukaemia
3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were an estimated 21,450 new patients with acute myeloid leukaemia (AML) and 11,180 AML-related deaths […]

touchHAEMATOLOGY

Education, Conference Coverage and Articles

Speciality Filter
Or View our Specialities Page

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
50 mins
touchCONGRESS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Gianantonio Rosti, Dr Carla Boquimpani, Prof. Dr. med. Susanne Saussele

Watch this touchCONGRESS activity exploring advances in treatments for patients with CML, based on data from 2024 congresses, including EHA and ESH-iCMLf.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.

33 mins
touchEXPERT OPINIONS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Andrew Wei, Prof. Agnieszka Wierzbowska, Prof. Gert Ossenkoppele

Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.

Want to be featured in touchReviews in Haematology?

Share your knowledge, influence clinical practices and enhance patient care in Haematology today!

  • Peer-reviewed, free-to-access
  • Accepting reviews, research and editorials
  • No article processing fees
  • Digital features and plain language summaries
  • Multichannel content distribution for maximum visibility
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were ...

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Histone-lysine N-methyltransferase 2A rearrangements (KMT2Ar) and mutant nucleophosmin 1 (mNPM1) occur in approximately 5–10% and 30% of patients with acute myeloid leukaemia (AML), respectively.1,2 Both mutations are associated with the founding events in the development of leukaemia.1 In particular, KMT2Ar functions ...

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Frontline treatment with azacitidine plus venetoclax (AZA/VEN) significantly improved remission rates and survival duration for older, frail and high-risk patients with acute myeloid leukaemia (AML) in the pivotal VIALE-A trial.1 The combination is approved for use in this setting,2 ...

62 mins
touchSATELLITE SYMPOSIUM
Mark CompleteCompleted
BookmarkBookmarked
Prof. Susanne Saussele, Prof. Massimo Breccia, Prof. Valentín García Gutiérrez

Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.

29 mins
touchIN CONVERSATION
Mark CompleteCompleted
BookmarkBookmarked

Two specialists in chronic myeloid leukaemia (CML) discuss the mechanisms of action and latest data for current and emerging treatments and how they may impact the management of CML after two prior lines of therapy.

37 mins
touchMDT
Mark CompleteCompleted
BookmarkBookmarked
Prof. Régis Peffault de Latour, Dr Will Evans, Ms Jess Ratcliffe

Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.

47 mins
touchEXPERT OPINIONS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Dr. med. Uwe Platzbecker, Prof. Agnieszka Wierzbowska, Prof. Valeria Santini

Three experts consider the potential of immune-based strategies to treat MDS and AML.

56 mins
touchCONGRESS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Michael Heuser, Dr Yishai Ofran, Dr Esther Oliva

Watch this two-part activity exploring recent developments in the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA 2022 Hybrid Congress.

65 mins
touchCONGRESS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Giuseppe Saglio, Prof. Dietger Walter, Niederwieser, Prof. Francois-Xavier Mahon

Watch this two-part activity exploring recent data on current and emerging treatments for CML. Filmed following the EHA Hybrid Conference 2022.

46 mins
touchMDT
Mark CompleteCompleted
BookmarkBookmarked
Prof. Dr. Andreas Hochhaus, Dr Kim Bee Tan, Mr Johan De Munter, Ms Jelena Čugurović

Watch chronic myeloid leukaemia (CML) specialists within a multidisciplinary team, plus a CML patient advocate, discuss the later-line management of CML.

61 mins
touchCONGRESS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Pierre Fenaux, Prof. Andrew Wei, Dr Esther Oliva

Watch this two-part activity exploring recent data on new and emerging treatments for patients with higher-risk MDS and newly diagnosed AML, filmed following the ASH 2021 Annual Meeting & Exposition.

38 mins
touchEXPERT OPINIONS
Mark CompleteCompleted
BookmarkBookmarked
Miss Simona Degli Esposti, Prof. Ibrahim Yakoub-Agha, Dr Paula Rodríguez-Otero

Watch leading experts review adverse event management with BCMA-targeting multiple myeloma therapies, and consider the role of the multidisciplinary team.

Load More...

Editorial Board

Introducing the Expert Faculty of touchHAEMATOLOGY, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.

View All Members

John Mascarenhas

Faculty member

Myelodysplastic Syndrome

Close Popup

John Mascarenhas

Faculty member

Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, USA

New York, USA

Biography

Dr John Mascarenhas is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. Dr Mascarenhas is the Director of Center of Excellence in Blood Cancers and Myeloid Disorders, Director of the Adult Leukemia Program, and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai.  As a clinical investigator in malignant hematology with a focus in translational research involving MPNs, he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary acute leukemia. 

Bernd Jilma

Faculty member

Bernd Jilma

Faculty member

Coagulation, thrombotic events

Close Popup

Bernd Jilma

Faculty member

Full Professor and Deputy Head of the Department of Clinical Pharmacology at the Medical University of Vienna, Vienna, Austria

Vienna, Austria

Biography

Bernd Jilma, MD, is a Full Professor and Deputy Head of the Department of Clinical Pharmacology at the Medical University of Vienna. His scientific interests encompass coagulation research, anaphylaxis, rare diseases, biologics, and vaccines. Since 2001, Dr. Jilma has been a principal investigator in phase I, II, and III clinical trials, including multinational studies. He has published over 525 peer-reviewed articles in esteemed journals such as NEJM, Lancet, Lancet Infect Dis, JACC, Blood, Circulation, and Am J Respir Crit Care Med.

John Mascarenhas

Faculty member

Kristen Sanfilippo

Faculty member

Kristen Sanfilippo

Faculty member

Thrombosis

Close Popup

Kristen Sanfilippo

Faculty member

Hematologist, Division of Hematology at Washington University School of Medicine St. Louis and Staff Physician, Division of Hematology/Oncology at John Cochran Veterans Administration Medical Center, St. Louis, MO, USA

St. Louis, MO, USA

Biography

Dr. Kristen Sanfilippo is a Hematologist in the Division of Hematology at Washington University School of Medicine St. Louis and a Staff Physician in the Division of Hematology/Oncology at John Cochran Veterans Administration Medical Center St. Louis, USA. She is a co-chair of the International Society on thrombosis and Haemostasis Scientific and Standardization Committee for Hemostasis and Malignancy.  In addition to clinical training in hematology/oncology, she earned a Masters in Population Health Sciences at Washington University St. Louis School of Medicine in 2012. Since completion of her Master’s degree, Dr. Sanfilippo has focused her research on health outcomes in patients with venous thromboembolism with a focus on cancer-associated thrombosis. Her research group developed and validated a risk prediction model, IMPEDE VTE, to identify patients with multiple myeloma starting chemotherapy at high-risk of venous thromboembolism. In addition, through a collaboration with a research team at University of Washington School of Medicine, they developed the SAVED score to predict risk of venous thromboembolism in multiple myeloma patients receiving an immunomodulatory agent. Both IMPEDE VTE and the SAVED score are recommended as the risk prediction models of choice by the National Comprehensive Cancer Network (NCCN) clinical guidelines. Her clinical and research interests continue to focus on venous thromboembolism and cancer-associated thrombosis with her current work focused on understanding risk-factors for anticoagulant-related bleeding in patients with cancer.

Bernd Jilma

Faculty member

Erik Aerts

Faculty member

Erik Aerts

Faculty member

Leukaemia

Close Popup

Erik Aerts

Faculty member

Nurse Manager at University Hospital Zürich, Zürich, Switzerland

Zürich, Switzerland

Biography

Erik Aerts is a Nurse Manager at University Hospital Zürich in Zürich, Switzerland, where he leads the nursing operations in the Department of Medicine Oncology and Haematology. He pioneered the first haematology-oncology nursing course in Switzerland, providing nurses with the opportunity to specialize in haematology and oncology. With 30 years of nursing experience across diverse settings and specialties, his focus has been on haematology and haematopoietic stem cell transplantation (HSCT).

Mr. Aerts also serves as President of several professional groups, including the Haematology Nurses & Healthcare Professionals Group and the European Group for Blood and Marrow Transplantation Nurses Group.

Kristen Sanfilippo

Faculty member

John Mascarenhas

Faculty member
Advertisement
  • touchHAEMATOLOGY touchHAEMATOLOGY

    Register Now!

    Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

    • Save your progress for video
    • Keep track of your CME credits
    • Add personalised learning notes
    • Receive updates from course leaders and faculty
    • Be the first to hear about new and exciting interactive learning opportunities
    Close Popup